Skip to main content
SpringerLink
Log in

The effect of recombinant interleukin 2 in combination with mitomycin C on advanced cancer

  • Short Communication
  • Published:
The Japanese journal of surgery Aims and scope Submit manuscript

Abstract

We recently discovered that the ability of cancer patients to generate lymphokine-activated killer (LAK) cells became remarkably augmented after mitomycin C (MMC) administration. Based on our clinical findings, we designed a treatment regimen comprised of MMC 12 mg/m2 given intravenously on day 1 and recombinant interleukin 2 (rIL 2) 700 U/m2 given intravenously every 12 hr from day 4 through day 8, when the generation of LAK cells had been shown to be markedly increased. Ten patients with various advanced carcinomas for which standard therapy had failed or no standard therapy was available, were treated with this regimen. Of these ten, three had a partial response and three others had a minor response. Fevers were common and anemia occurred in four patients, but nevertheless, severe toxicity was not encountered. These results indicated that rIL 2 in combination with MMC might be effective against advanced carcinoma without causing severe toxicity when these drugs are used in an appropriate combination.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Ogura T, Shindo H, Shinzato O, Namba M, Masuno T, Inoue K, Kishimoto S, Yamamura Y.In vitro tumor killing by peritoneal macrophages from mitomycin C treated rats. Cancer Immunol Immunother 1982; 13: 112–117.

    Article  PubMed  CAS  Google Scholar 

  2. Shindo H, Ogura T, Masuno T, Hayashi S, Kishimoto S. Induction of activated macrophages by intraperitoneal injection of mitomycin C in mice. Cancer Immunol Immunother 1985; 20: 145–150.

    Article  PubMed  CAS  Google Scholar 

  3. Akiyoshi T, Arinaga S, Tsuji H. Augmentation of the generation of cell-mediated cytotoxicity in culture by mitomycin C. Cancer Immunol Immunother 1987; 24: 259–262.

    Article  PubMed  CAS  Google Scholar 

  4. Arinaga S, Akiyoshi T, Tsuji H. Augmentation of the generation of OK-432 activated killer cells after a single dose of mitomycin C in cancer patients. Int J Immunopharmacol 1988; 10: 47–51.

    Article  PubMed  CAS  Google Scholar 

  5. Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, Matory YL, Skibber JM, Shiloni E, Vetto JT, Seipp CA, Simpson C, Reichert CM. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 1985; 313: 1485–1492.

    Article  PubMed  CAS  Google Scholar 

  6. Rosenberg SA, Lotze M, Muul LM, Chang AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT, Seipp CA, Simpson CG, White DE. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 1987; 316: 889–897.

    Article  PubMed  CAS  Google Scholar 

  7. West WH, Tauer KW, Yannelli JR, Marshall GD, Orr DW, Thurman GB, Oldham RK. Constant-infusion recombinant interleukin-2 in adoptive immuno-therapy of advanced cancer. N Engl J Med 1987; 316: 898–905.

    Article  PubMed  CAS  Google Scholar 

  8. Lotze MT, Chang AE, Seipp CA, Simpson C, Vetto JT, Rosenberg SA. High-dose recombinant interleukin 2 in the treatment of patients with disseminated cancer: response, treatment-related morbidity, and histologic findings. JAMA 1986; 256: 3117–3124.

    Article  PubMed  CAS  Google Scholar 

  9. Nanbara S, Arinaga S, Akiyoshi T. Augmentation of the generation of lymphokine-activated killer cells after a single dose of mitomycin C in cancer patients. Cancer Immunol Immunother 1989; in press.

  10. Hinuma S, Onda H, Naruo K, Ichimori Y, Koyama M, Tsukamoto K. Translation of interleukin 2 mRNA from human peripheral blood leukocytes in Xenopus oocytes. Biochem Biophys Res Commun 1982; 109: 363–369.

    Article  PubMed  CAS  Google Scholar 

  11. Lotze MT, Matory YL, Ettinghausen SE, Rayner AA, Sharrow SO, Seipp CA, Custer MC, Rosenberg SA.In vivo administration of purified human interleukin 2: II. Half-life, immunologic effects, and expansion of peripheral lymphoid cellsin vivo with recombinant IL 2. J Immunol 1985; 135: 2865–2874.

    PubMed  CAS  Google Scholar 

  12. Crooke ST, Bradner WT. Mitomycin C: A review. Cancer Treat Rev 1976; 3: 121–139.

    PubMed  CAS  Google Scholar 

  13. Bisel HF. Management of locally advanced and disseminated breast cancer-chemotherapy. Cancer 1980; 46: 1079–1083.

    Article  PubMed  CAS  Google Scholar 

  14. Kisner DL, McDonald JS. The impact of chemotherapy on the treatment of gastric cancer: In: Cancer Chemotherapy, 1. Muggia FM, ed. Cancer Treatment and Research. Martinus Nijhoff 1983; 2: 281–301.

Download references

Author information

Authors and Affiliations

  1. The Department of Surgery, Medical Institute of Bioregulation, Kyushu University, 69, 874, Beppu, Japan

    Tsuyoshi Akiyoshi MD, Shinya Arinaga, Shigeru Nanbara, Nobuya Karimine, Hiroshi Inoue, Kiyoshi Takamuku, Ryoji Abe, Daisuke Watanabe, Masaaki Nagamatsu, Hideo Matsuoka & Hiroaki Ueo

Authors
  1. Tsuyoshi Akiyoshi MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shinya Arinaga
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shigeru Nanbara
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Nobuya Karimine
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hiroshi Inoue
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Kiyoshi Takamuku
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ryoji Abe
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Daisuke Watanabe
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Masaaki Nagamatsu
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Hideo Matsuoka
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Hiroaki Ueo
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Akiyoshi, T., Arinaga, S., Nanbara, S. et al. The effect of recombinant interleukin 2 in combination with mitomycin C on advanced cancer. The Japanese Journal of Surgery 20, 365–368 (1990). https://doi.org/10.1007/BF02470676

Download citation

  • Received:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02470676

Key Words

Search

Navigation